TIDMENTL 
 
 




  Entelos, Inc. ("Entelos" or the "Company") today announces that the Company's shareholders overwhelmingly voted to approve a proposal to de-list its shares of common stock from the AIM Exchange, at its 2009 Annual Meeting of Stockholders held on June 23, 2009. The proposal was approved by a vote of 99.9% of the shares voting. 62% of the issued and outstanding shares eligible to vote, were voted. As previously announced, the Company's senior management and Board of Directors has been considering a variety of strategic transactions over the past year, including seeking new significant equity investors, in order to provide the platform necessary for the Company to continue to grow its business. The Company's Board of Directors has determined that it would be in the best interests of the Company and its stockholders and other stakeholders to seek a delisting of its shares from AIM. 


 




  The Company's Chairman of the Board, Jon Saxe, said, "We are pleased that the Company's shareholders are supporting this transition that we view as an important step for the Company's future. This delisting is contemplated to save us significant costs, making it possible to devote more resources to achieve profitable growth over time and could enable investments and flexibility not available to us as a listed company." 


 




  Under the AIM Rules, it is a requirement that any delisting from the AIM Exchange must be approved by not less than 75% of stockholders voting at a stockholders meeting. As announced on June 1, 2009, the cancellation of dealings will take effect at 7:00 a.m. on July 1, 2009 at which time the delisting will be completed and the Company's common stock will no longer trade on the AIM Exchange. 


 




  The Company is also pleased to announce the re-election of the following Directors of the Company, again, by an overwhelming majority: George Scangos for a one year term, Jon Saxe, for a three year term and Simon Best, for a three year term. 


 




  Finally, the stockholders ratified the appointment of Deloitte & Touche, LLP as the Company's independent auditors for the fiscal year ending December 31, 2009. 


 




  A proxy statement containing the proposals is available on the Company's website at www.entelos.com. 


 




  About Entelos 


 




  Entelos, Inc. (www.entelos.com) is a US-based life sciences company applying next-generation predictive technologies to revolutionize the way medicines are discovered, developed, and utilized. The Company leverages its proprietary in silico disease models, "virtual human" technology, and toxicology reference systems to develop safer and more effective drugs, improve the quality of health-related consumer products, and deliver on the promise of personalized medicine. Entelos provides customized products, technology and research services to global pharmaceutical, health-care, and consumer products companies in safety testing, arthritis, cardiovascular diseases, asthma, obesity, diabetes, hematopoeisis (anemia), cholesterol metabolism, skin sensitization, and personal care products.
Entelos Regs (LSE:ENTL)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Entelos Regs Charts.
Entelos Regs (LSE:ENTL)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Entelos Regs Charts.